ASCO 2018: Treatment of Metastatic Hormone-Sensitive Prostate Cancer and Implications for Subsequent Management
Chicago, IL (UroToday.com) Neeraj Agarwal provided a comprehensive overview of the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Three general topics were reviewed – the current standard of care for men with (mHSPC), the role of definitive therapy of primary prostate cancer (PC ) in the setting of mHSPC, and the implication of the upfront use of novel therapies on subsequent treatments in the setting of metastatic castrate-resistant prostate cancer (mCRPC).
ASCO 2018: Pembrolizumab plus Enzalutamide in mCRPC: Extended Follow Up
Chicago, IL (UroToday.com) While PD-1 inhibitors have made a marked impact on the survival of many patients with solid tumors, metastatic castration-resistant prostate cancer remains challenging to treat with checkpoint inhibitors and most patients are refractory to single-agent PD-1 inhibition on clinical trials. It has been reported that patients who progress on enzalutamide have increased PD-L1/2+ dendritic cells in blood compared to those patients who are responding to therapy1. Thus, it has been hypothesized that patients who progress on enzalutamide may have a primed tumor microenvironment which may sensitive them to PD-1 inhibition.
ASCO 2018: Enzalutamide Plus CC-115 in Men with mCRPC: A Phase 1b Prostate Cancer Clinical Trials Consortium Study
Chicago, IL (UroToday.com) Enzalutamide is an oral anti-androgen receptor inhibitor which improves overall survival in men with castration-resistant prostate cancer before and after exposure to chemotherapy1,2. Overall response rates range from 29% to 60% depending on the study population with a median PFS of 19.4 months in STRIVE3. However, all patients will eventually progress on therapy, many due to AR gene rearrangements causing truncated AR splice variants that lack the AR ligand-binding domain4. Thus, additional novel therapies are necessary to modulate androgen receptor signaling.
ASCO 2018: Balancing Toxicities, and Therapeutics Perspective
Chicago, IL (UroToday.com) Celestia Higano, MD, gave an excellent talk on the topic of treatment toxicities in patients with metastatic hormone-sensitive prostate cancer (MHSPC). Dr. Higano began with the most important question in this topic, on how to decide which therapy to use in MHSPC. One of the options is to decide by volume of metastatic disease.
ASCO 2018: Long-Term Androgen Deprivation, With or Without Radiotherapy, in Locally-Advanced Prostate Cancer: Updated Results from a Phase III Randomized Trial
Chicago, IL (UroToday.com) There is a need to know whether there is a beneficial effect for the addition of external beam radiation therapy (EBRT) to long term androgen deprivation therapy (ADT), in patients with locally advanced prostate cancer. The authors of this study presented long term results (7.3 year median follow-up) of this specific trial published in 2012.
ASCO 2018: Optimal Patient Selection/Stratification Perspective
Chicago, IL (UroToday.com) Charles Ryan, MD, gave an excellent talk on the optimal patient selection for prostate cancer. When assessing early failure and early death in studies comparing abiraterone and androgen deprivation therapy (ADT), it is evident that approximately 22% of patients are dead 2 years after starting ADT + abiraterone. This death rate rises to 33% after 3 years of follow-up.
ASCO 2018: Ten Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1,503 Patients With Intermediate Risk Prostate Cancer
Chicago, IL (UroToday.com) Comparison of definitive therapy of localized prostate cancer is of great interest to both urologists, radiation oncologists and medical oncologists. In this study the authors present data on 10-year treatment outcomes of radical prostatectomy (RP) vs. external beam radiation therapy (EBRT) vs. brachytherapy (BT) for patients with intermediate risk prostate cancer (IRPC).